SEARCH:   Advanced

Blood, 15 October 2006, Vol. 108, No. 8, pp. 2755-2763. Prepublished online as a Blood First Edition Paper on June 27, 2006; DOI 10.1182/blood-2006-02-005488. This Article Full Text Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2006-02-005488v1 108/8/2755    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chng, W. J. Articles by Bergsagel, P. L. Search for Related Content PubMed PubMed Citation Articles by Chng, W. J. Articles by Bergsagel, P. L. Related Collections Neoplasia Gene Expression Genomics Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma Wee J. Chng, Roelandt F. Schop, Tammy Price-Troska, Irene Ghobrial, Neil Kay, Diane F. Jelinek, Morie A. Gertz, Angela Dispenzieri, Martha Lacy, Robert A. Kyle, Philip R. Greipp, Renee C. Tschumper, Rafael Fonseca, and Peter Leif Bergsagel From the Department of Hematology-Oncology, Mayo Clinic Scottsdale, AZ; Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN; Dana Faber Cancer Institute, Boston, MA; Division of Internal Medicine, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN; Department of Immunology and Division of Hematology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN. Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Gene expression relates WM to CLL Adrian Wiestner Blood 2006 108: 2499-2500. [Full Text] [PDF] This article has been cited by other articles: L. R. Goldin, M. Bjorkholm, S. Y. Kristinsson, I. Turesson, and O. Landgren Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia Haematologica, May 1, 2009; 94(5): 647 - 653. [Abstract] [Full Text] [PDF] A. M. Roccaro, A. Sacco, C. Chen, J. Runnels, X. Leleu, F. Azab, A. K. Azab, X. Jia, H. T. Ngo, M. R. Melhem, et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia Blood, April 30, 2009; 113(18): 4391 - 4402. [Abstract] [Full Text] [PDF] P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar, J. McCoy, J. Crowley, E. M. Ocio, R. Garcia-Sanz, S. P. Treon, et al. International prognostic scoring system for Waldenstrom macroglobulinemia Blood, April 30, 2009; 113(18): 4163 - 4170. [Abstract] [Full Text] [PDF] E. Braggio, J. J. Keats, X. Leleu, S. Van Wier, V. H. Jimenez-Zepeda, R. Valdez, R. F.J. Schop, T. Price-Troska, K. Henderson, A. Sacco, et al. Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-{kappa}B Signaling Pathways in Waldenstrom's Macroglobulinemia Cancer Res., April 15, 2009; 69(8): 3579 - 3588. [Abstract] [Full Text] [PDF] W. J. Chng, E. D. Remstein, R. Fonseca, P. L. Bergsagel, J. A. Vrana, P. J. Kurtin, and A. Dogan Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications Blood, January 15, 2009; 113(3): 635 - 645. [Abstract] [Full Text] [PDF] X. Leleu, L. Xu, X. Jia, A. Sacco, M. Farag, Z. R. Hunter, A.-S. Moreau, H. T. Ngo, E. Hatjiharissi, A. W. Ho, et al. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia Blood, January 15, 2009; 113(3): 626 - 634. [Abstract] [Full Text] [PDF] S. Adamia, A. A. Reichert, H. Kuppusamy, J. Kriangkum, A. Ghosh, J. J. Hodges, P. M. Pilarski, S. P. Treon, M. J. Mant, T. Reiman, et al. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia Blood, December 15, 2008; 112(13): 5111 - 5121. [Abstract] [Full Text] [PDF] S. Y. Kristinsson, M. Bjorkholm, L. R. Goldin, M. L. McMaster, I. Turesson, and O. Landgren Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden Blood, October 15, 2008; 112(8): 3052 - 3056. [Abstract] [Full Text] [PDF] S. Poulain, I. Dervite, X. Leleu, V. Coiteux, P. Duthilleul, and P. Morel The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less Haematologica, July 1, 2008; 93(7): 1109 - 1111. [Full Text] [PDF] X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia Blood, May 15, 2008; 111(10): 5068 - 5077. [Abstract] [Full Text] [PDF] M. Lehto, M. I. Mayranpaa, T. Pellinen, P. Ihalmo, S. Lehtonen, P. T. Kovanen, P.-H. Groop, J. Ivaska, and V. M. Olkkonen The R-Ras interaction partner ORP3 regulates cell adhesion J. Cell Sci., March 1, 2008; 121(5): 695 - 705. [Abstract] [Full Text] [PDF] X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia Blood, December 15, 2007; 110(13): 4417 - 4426. [Abstract] [Full Text] [PDF] S. Trudel, Z. H. Li, J. Rauw, R. E. Tiedemann, X. Y. Wen, and A. K. Stewart Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma Blood, June 15, 2007; 109(12): 5430 - 5438. [Abstract] [Full Text] [PDF] E. Hatjiharissi, H. Ngo, A. A. Leontovich, X. Leleu, M. Timm, M. Melhem, D. George, G. Lu, J. Ghobrial, Y. Alsayed, et al. Proteomic Analysis of Waldenstrom Macroglobulinemia Cancer Res., April 15, 2007; 67(8): 3777 - 3784. [Abstract] [Full Text] [PDF] T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma Blood, April 1, 2007; 109(7): 3024 - 3030. [Abstract] [Full Text] [PDF] Genetic Profile of Waldenstrom Macroglobulinemia Journal Watch Oncology and Hematology, November 27, 2006; 2006(1127): 1 - 1. [Full Text]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020